Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2353MR)

This product GTTS-WQ2353MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2353MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6229MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ11677MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ12192MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ14798MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ6718MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ5613MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ12510MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ1431MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACC-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW